Genetic determinants of ASMS pharmacokinetics
| Antiepileptic drug | Genetic polymorphisms | Implications | Reference(s) |
|---|---|---|---|
| Valproic acid | CYP2C93, CYP2A64 | Influence on plasma concentrations may require dosage adjustments | [14] |
| Phenytoin | CYP2C92, CYP2C93, CYP2C19*2 | Reduced metabolism rate, unclear effects on CYP2C19*2, need for dosage adjustments.CYP2C19 mutations: Carriers may require reduced maintenance doses.CYP2C93: Associated with increased risk of severe cutaneous adverse reactions | [15–17] |
AS: Conceptualization, Writing—original draft. KH: Writing—original draft, Writing—review & editing. A Zafar: Validation, Writing—review & editing. A Zainab: Conceptualization, Writing—original draft, Writing—review & editing. SA: Conceptualization, Supervision. All authors read and approved the submitted version.
The authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2024.